Cellebrite DI (CLBT) — Capital Reinvestment Ratio
Latest as of December 2025:
0.05x
Cellebrite DI (CLBT) has a Capital Reinvestment Ratio of 0.05x as of December 2025, meaning it reinvests 0% of its operating cash flow ($82.23 Million) in capital expenditures ($3.96 Million). See free cash flow generation of Cellebrite DI to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.05x
Capex / Operating Cash Flow
Operating Cash Flow
$82.23 Million
USD
Capital Expenditures
$3.96 Million
USD
Data as of
Dec 2025
Most recent filing
Cellebrite DI Capital Reinvestment Ratio (2019–2025)
This chart tracks Cellebrite DI's Capital Reinvestment Ratio across 7 annual periods.
Annual Capital Reinvestment Ratio for Cellebrite DI (2019–2025)
Year-by-year Capital Reinvestment Ratio for Cellebrite DI from 2019 to 2025. For live market cap and broader valuation context, see CLBT market cap.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.08x | $168.96 Million | $13.22 Million | ▼ -2.5% |
| 2024 | 0.08x | $132.17 Million | $10.61 Million | ▲ +3.5% |
| 2023 | 0.08x | $102.06 Million | $7.92 Million | ▼ -82.4% |
| 2022 | 0.44x | $20.58 Million | $9.09 Million | ▲ +96.2% |
| 2021 | 0.22x | $36.05 Million | $8.11 Million | ▲ +142.1% |
| 2020 | 0.09x | $66.51 Million | $6.18 Million | ▼ -75.9% |
| 2019 | 0.38x | $16.13 Million | $6.21 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow